<DOC>
	<DOCNO>NCT00049218</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Vaccines make gene-modified virus may make body build immune response kill tumor cell . Combining vaccine therapy chemotherapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness chemotherapy follow adenovirus p53 vaccine therapy treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Followed By Vaccine Therapy Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose autologous dendritic cell-adenovirus p53 vaccine , administer standard chemotherapy , patient extensive stage small cell lung cancer . - Determine toxicity regimen patient . - Determine development anti-p53-specific immune response patient treatment regimen . - Determine tumor response rate , time progression , overall survival patient treat regimen . - Determine frequency anti-adenovirus immune response patient treatment regimen . OUTLINE : This dose-escalation study autologous dendritic cell-adenovirus p53 vaccine . Patients undergo leukapheresis dendritic cell culture . Adenovirus carry p53 gene particle add dendritic cell make vaccine . Leukapheresis perform chemotherapy 8 week last dose chemotherapy patient already start chemotherapy . Patients receive standard chemotherapy receive vaccine . The recommended regimen carboplatin IV 1 hour day 1 etoposide IV 1 hour day 1-3 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients progressive disease ( PD ) 6 week chemotherapy remove study . Patients follow day 140 every 3 month thereafter . PROJECTED ACCRUAL : A total 43-58 patient ( 3-18 phase I 40 phase II ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm small cell lung cancer Extensive stage disease Measurable disease No uncontrolled central nervous system ( CNS ) metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy Not specify Hematopoietic White blood count ( WBC ) great 3,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hematocrit great 25 % Hepatic Bilirubin le 2.0 mg/dL Renal Creatinine le 2.0 mg/dL Immunologic HIV negative No serious ongoing infection No preexisting immunodeficiency No known preexist autoimmune disorder Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy At least 4 week since prior steroid ( vaccination ) No concurrent chronic steroid ( vaccination ) Radiotherapy At least 2 week since prior radiotherapy ( vaccination ) Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>